News

Zuplenz, launched in the US in July 2015, is an anti-emetic, which does not need to be injected or swallowed, offering patients a differentiated alternative. Midatech expects that

Keith Flaherty, M.D., Director of the Termeer Center for Targeted Therapy at Massachusetts General Hospital and Associate Professor at Harvard Medical School has been named the Principal Investigator.

This approval marks the second FDA-approved indication in advanced melanoma for KEYTRUDA, which is now the first anti-PD-1 therapy approved for previously untreated advanced melanoma patients regardless of

Under the deal, Janssen will acquire exclusive rights to Bavarian’s MVA-BN technology for use in a prime-boost vaccine regimen together with its AdVac technology to target all cancers

The committee recommended approval for the company’s lesinurad 200 mg tablets, in combination with a xanthine oxidase inhibitor (XOI), for the adjunctive treatment of of hyperuricaemia in adults

GSK’s global HIV business, ViiV Healthcare, has signed two separate transactions, which are expected to complete independently during the first half of next year. The deals are subject

The trial will evaluate select patients exhibiting genetic alterations in the tyrosine kinase signaling pathways, RET, DDR and Trk, which are known oncogenic drivers. The study will also

Both of these diseases are ultra-rare, with prevalences in the United States believed to be approximately 3,000 and 1,000-1,500 patients, respectively. Catalyst CEO Patrick McEnany said: "The completion

Founding partners participating in the program include: argenx, Crystal Bioscience and Sevion Therapeutics. The program combines Tetragenetics’ unique and proprietary antigen production capabilities with each partner’s novel antibody